Optune is the second product from Zai Lab, alongside PARP inhibitor ZEJULA (niraparib) for treating ovarian cancer, in the Asian market. Hong Kong is considered to be the
The post Zai Lab launches Optune in Hong Kong to treat glioblastoma multiforme appeared first on Compelo Medical Devices.
Original Article: Zai Lab launches Optune in Hong Kong to treat glioblastoma multiforme